Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for China National Accord Medicines's EV-to-FCF or its related term are showing as below:
SZSE:200028'
s EV-to-FCF Range Over the Past 10 Years
Min: -232.8 Med: 12.69 Max: 52.98
Current: -179.95
During the past 13 years, the highest EV-to-FCF of China National Accord Medicines was 52.98. The lowest was -232.80. And the median was 12.69.
SZSE:200028's EV-to-FCF is ranked worse than 100% of 70
companies
in the Medical Distribution industry
Industry Median: 17.425
vs SZSE:200028: -179.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China National Accord Medicines (SZSE:200028) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China National Accord Medicines's PE Ratio (TTM) for today is calculated as:
China National Accord Medicines's share price for today is HK$12.07.
China National Accord Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China National Accord Medicines EV-to-FCF Related Terms
China National Accord Medicines EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:200028 vs MCK, COR, CAH: EV-to-FCF Comparison
For the Medical Distribution subindustry, China National Accord Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's EV-to-FCF falls into.
China National Accord Medicines's current Enterprise Value is HK$13,811 Mil.
China National Accord Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Accord Medicines (SZSE:200028) has a EV-to-FCF of -179.95 as of Sep. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China National Accord Medicines and its competitors. According to the industry distribution chart, China National Accord Medicines ranks #999999 out of 70 companies in the Medical Distribution industry.
Is China National Accord Medicines' EV-to-FCF too high?
China National Accord Medicines' current EV-to-FCF is -179.95. Based on the distribution chart, China National Accord Medicines ranks #999999 out of 70 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #999999 out of 70 companies for EV-to-FCF. This places China National Accord Medicines in the lower half of its industry. The industry median EV-to-FCF is 17.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.43, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current EV-to-FCF is -179.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.64, compared to a current price of HK$12.07 — trading 11.5% below its estimated fair value. The current EV-to-FCF is -179.95. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current EV-to-FCF is -179.95 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.07 is trading 11.5% below its estimated GF Value™ of HK$13.64.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
EV-to-FCF: -179.95
GF Value™: HK$13.64 vs. price of HK$12.07 (11.5% below fair value)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
